2025 Annual Meeting | C137 - Drug Pricing in 2025: What’s Next for Patient’s, Practices, Providers, and Institutions

Date Tuesday 04/08/25

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Location San Diego Convention Center | 29B

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Kavita Nair, PhD, FAAN

Topic(s) Practice, Policy, and Ethics

Learning Objectives The year 2025 and beyond brings many new developments and changes to drug pricing. These include the continuing impact of key legislation such as The Inflation Reduction Act (IRA) provisions for Medicare drug price negotiations, the state of innovation in the neurology drug pipeline, and how pharmacy benefit managers (PBM) are impacting the prior authorization burden on neurology practices. Through presentations from experts on the IRA negotiation team, leaders in the pharmaceutical industry and payer experts, attendees will be given the opportunity to participate in a spirted panel discussion with experts and faculty on these topics.

CME Available 2.00 CME credits

Core Competencies Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator

Teaching Styles Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:20 AM PDT	Speaker	The US Drug Distribution Sytem Kavita Nair, PhD, FAAN
07:20 AM - 07:40 AM PDT	Speaker	The Pharmaceutical Industry: Trends in New Neurology Drug Development Jennifer Graff, PharmD
07:40 AM - 08:00 AM PDT	Speaker	Payers and Neurology Drugs: 2025 and Beyond Christine Hale, MD, MPH
08:00 AM - 08:20 AM PDT	Speaker	The Future of Drug Pricing for Private Neurology Practices Brad C. Klein, MD, MBA, FAAN
08:40 AM - 09:00 AM PDT	Discussion	Panel Discussion Kavita Nair, PhD, FAAN, Brad C. Klein, MD, MBA, FAAN, Christine Hale, MD, MPH, Jennifer Graff, PharmD

Faculty Disclosures
Kavita Nair, PhD, FAAN	Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MJH Lifesciences. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Patient Experience. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MHJ Life Sciences. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for ICER. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS. The institution of Dr. Nair has received research support from Sanofi Genzyme. The institution of Dr. Nair has received research support from Kyverna Therapeutcis. Dr. Nair has a non-compensated relationship as a Board Member with Center for Improving Value in Healthcare that is relevant to AAN interests or activities.
Brad C. Klein, MD, MBA, FAAN	Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly and Company. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AbbVie. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Scilex. The institution of Dr. Klein has received research support from AbbVie. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Shareholder with AppsbyDocs, LLC. Dr. Klein has a non-compensated relationship as a Chair, Practice Management Committee with American Headache Society that is relevant to AAN interests or activities.
Jennifer Graff, PharmD	The institution of Jennifer Graff, PharmD has received research support from Reagan Udall Foundation for the FDA. The institution of Jennifer Graff, PharmD has received research support from Tufts New Drug Developoment ParadiGmS (NEWDIGS). The institution of Jennifer Graff, PharmD has received research support from We Work for Health. The institution of Jennifer Graff, PharmD has received research support from EveryLife Foundation for Rare Diseases. The institution of Jennifer Graff, PharmD has received research support from Real Endpoints. Jennifer Graff, PharmD has received research support from National Pharmaceutical Council.
Christine Hale, MD, MPH	No disclosure on file

��ɫ��

��ɫ��